A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder

Journal of Psychiatric Practice

Volumn 12, Issue 4, 2006, Pages 214-222

  MacMillan, Carlene M ^a,b   Korndörfer, Sergio R ^a   Rao, Sneha ^a   Fleisher, Carl A ^a   Mezzacappa, Enrico ^a   Gonzalez Heydrich, Joseph ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adolescents; Aggression; Bipolar disorder; Children; Divalproex; Oxcarbazepine

Indexed keywords

OXCARBAZEPINE; VALPROATE SEMISODIUM;

ADOLESCENT; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COORDINATION DISORDER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; IMPULSIVENESS; LOGORRHEA; MALE; MEDICAL RECORD REVIEW; MENTAL INSTABILITY; NAUSEA; PARKINSONISM; PSYCHOPHARMACOTHERAPY; RATING SCALE; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ADOLESCENT; ADULT; AGGRESSION; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33746824699     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200607000-00003     Document Type: Article

References (37)

1. World Health Organization. Investing in mental health. http://www.who.int/mental_health/media/en/investing_mnh.pdf , accessed June 22, 2006.
2. Soutullo CA, Chang KD, Díez-Suárez A, et al. Bipolar disorder in children and adolescents: International perspective on epidemiology and phenomenology. Bipolar Disord 2005;7:497-506.
3. Campbell M, Cueva JE. Psychopharmacology in child and adolescent psychiatry: A review of the past seven years. Part II. J Am Acad Child Adolesc Psychiatry 1995;34:1262-72.
4. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-51.
5. Gadow KD, Nolan E, Sprafkin J, et al. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: Effects of methylphenidate treatment. J Dev Behav Pediatr 1995;16:167-76.
6. Corrigan PW, Yudofsky SC, Silver JM. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Community Psychiatry 1993;44:125-33.
7. Malone RP, Luebbert J, Pena-Ariet M, et al. The Overt Aggression Scale in a study of lithium in aggressive conduct disorder. Psychopharmacol Bull 1994;30:215-18.
8. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
9. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-35.
10. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2002;41:1224-30.
11. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000;39:713-20.
12. Mota-Castillo M, Torruella A, Engels B, et al. Valproate in very young children: An open case series with a brief follow-up. J Affect Disord 2001;67:193-7.
13. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995;7:33-7.
14. Wroblewski BA, Joseph AB, Kupfer J, et al. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997;11:37-47.
15. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998;59:676-80.
16. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: A critical review. J Clin Psychiatr 2000;61:123-8.
17. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62:530-4.
18. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. Am J Psychiatry 2000;157:818-20.
19. Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: A randomized controlled clinical trial. J Clin Psychiatry 2003;64:1183-91.
20. Lehman RB. Effectiveness of divalproex in the treatment of disruptive behavior disorders in children: A retrospective chart review. Primary Psychiatry 2004;11:48-52.
21. Azouvi P, Jokic C, Attal N, et al. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: Results of an open trial. Brain Inj 1999;13:797-804.
22. Cueva J, Overall J, Small A, et al. Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996;35:480-90.
23. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5:627-35.
24. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004;79:273-7.
25. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990;5 (suppl 81):83-8.
26. Teitelbaum M. Oxcarbazepine in bipolar disorder. J Am Acad Child Adolesc Psychiatry 2001;40:993-4.
27. Gaudino MP, Smith MJ, Matthews DT. Use of oxcarbazepine for treatment-resistant aggression. Psychiatr Serv 2003;54:1166-7.
28. Davanzo P, Nikore V, Yehya N, et al. Oxcarbazepine treatment of juvenile-onset bipolar disorder. J Child Adolesc Psychopharmacol. 2004;14:344-5.
29. Emrich HM, Altmann H, Dose M, et al. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav 1983;19:369-72.
30. Raja M, Azzoni A. Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. Int J Neuropsychopharmacol 2003;6:409-14.
31. Gonzalez-Heydrich J, DeMaso DR, Irwin C, et al. Implementation of an electronic medical record system in a pediatric psychopharmacology program. Int J Med Inform 2000;57:109-16.
32. Abbott Laboratories. Depakote (divalproex sodium) prescribing information. http://www.rxabbott.com/pdf/depakote.pdf, accessed June 22, 2006.
33. Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/ trileptal.pdf, accessed June 22, 2006.
34. Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003;37:17-24.
35. Loscher W. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
36. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry 2003;64 (suppl 8): 5-8.
37. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.